Patents Examined by Jennifer Graser
  • Patent number: 9951342
    Abstract: The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the present invention provides methods for labelling and/or identifying bacteria. In some preferred embodiments, the present invention provides methods for the use of CRISPR loci to determine the potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence of a phage for increased virulence level.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: April 24, 2018
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Rodolphe Barrangou, Christophe Fremaux, Phillippe Horvath, Dennis Romero, Patrick Boyaval
  • Patent number: 9925230
    Abstract: Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: March 27, 2018
    Assignee: The University of Vermont and State Agricultural College
    Inventor: Ralph C. Budd
  • Patent number: 9914907
    Abstract: This disclosure describes modified photosynthetic microorganisms, including Cyanobacteria, that have a reduced amount of a light harvesting protein (LHP) and contain one or more introduced or overexpressed polynucleotides encoding one or more enzymes associated with lipid biosynthesis, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: March 13, 2018
    Assignee: LUMEN BIOSCIENCE, INC.
    Inventors: James Roberts, Michael Carleton, Damian Carrieri, Jason W. Hickman
  • Patent number: 9907849
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 6, 2018
    Assignees: Advaxis, Inc., Merck Sharp & Dohme Corp.
    Inventors: Robert Petit, David J. Mauro, Rodolfo F. Perini
  • Patent number: 9910042
    Abstract: The invention provides methods and compositions for detecting and diagnosing sexually transmitted infections using a string of epitopes (SOE) specific for detection of causative microorganisms. The antigenic epitopes may be single epitope sequences a plurality of epitope sequences joined by repeats of glycine (-GG-) and/or lysine (-KK-) to form a series of epitopes (SOE), or nucleotide sequences encoding one or more SOEs and host cells harboring said SOE nucleotide sequences. SOEs specific for highly immunogenic regions of proteins from Trichomonas, Treponema and Neisseria species are provided. SOEs to detect the presence of trichomonas species comprise regions from Trichomonas-sptciric aldolase, GAPDH, ?-enolase and ?-actinin proteins. Pharmaceutical compositions comprising SOEs can also be used as vaccines or to elicit an immune response to specific microorganisms.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 6, 2018
    Assignee: WASHINGTON STATE UNIVERSITY
    Inventor: John F. Alderete
  • Patent number: 9901633
    Abstract: The present invention is related to an immunogenic complex comprising a polymerized antigen, mannan and a dialdehyde, the composition comprising it and the use thereof as an immune response stimulator and vaccine, useful in the treatment of infectious diseases, neoplasms and allergies. Likewise, the invention relates to the method for obtaining said immunogenic complex, based on the antigen and mannan simultaneous polymerization and conjugation by using a dialdehyde.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: February 27, 2018
    Assignee: IMMUNOTEK, S.L.
    Inventors: José Luis Subiza Garrido-Lestache, Javier Cañada Vicinay, Irene Soria Castro, Enrique Fernández-Caldas Rodríguez, Ana Manzano Pérez, Bárbara Cases Ortega, Jesús Jiménez Barbero, Miguel Casanovas Vergés
  • Patent number: 9889186
    Abstract: An oral preparation for the prophylaxis or treatment of a disease with infection by a pathogen, containing a killed lactic acid bacterium expressing, on the surface, an antigen of the pathogen, or a microparticulated form thereof, which has an average particle size of 2.68-30 ?m. An oral preparation for inducing cellular immunity to a target antigen, containing a killed lactic acid bacterium expressing the target antigen on the surface or a microparticulated form thereof, which has a particle size of 2.68-30 ?m.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: February 13, 2018
    Assignees: MORISHITA JINTAN CO., LTD., BIOLEADERS CORPORATION
    Inventors: Takashi Nomura, Akiko Temma, Takahiro Nakazawa, Ryuichi Morishita, Il-Han Lee
  • Patent number: 9885051
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: February 6, 2018
    Assignees: The Arizona Board of Regents for and on Behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Patent number: 9884099
    Abstract: Vaccine, vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: February 6, 2018
    Assignees: The Board of Trustees of the University of Arkansas, The Texas A&M University System
    Inventors: John R. Barta, Luc Berghman, Srichaitanya Shivaramaiah, Olivia B. Faulkner, Lisa Bielke, Billy Hargis
  • Patent number: 9878024
    Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 30, 2018
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
  • Patent number: 9879069
    Abstract: There is disclosed compositions and methods relating to or derived from anti-OprF and anti-OprI antibodies. More specifically, there is disclosed fully human antibodies that bind OprF and OprI, OprF and OprI-antibody binding fragments and derivatives of such antibodies, and OprF and OprI-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having Pseudomonas aeruginosa infections. There is disclosed a method for treating or preventing Pseudomonas aeruginosa infections, wherein the disease is selected from the group consisting of burns, surgical site infections, diabetic foot ulcers, infected wounds, and cystic fibrosis.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: January 30, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Gunnar F. Kaufmann
  • Patent number: 9833503
    Abstract: Provided herein are methods and compositions for displaying a polypeptide on a tubular structure and uses of such displayed polypeptides in the production of antibodies or vaccines.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: December 5, 2017
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: John Mekalanos, Marek Basler
  • Patent number: 9834768
    Abstract: A nucleic acid molecule comprising a stem-loop structure, a nucleic acid complex comprising the nucleic acid molecule, a composition for delivering a target recognition sequence, and the composition comprising the nucleic acid complex. An artificial small ribonucleic acid of the stem-loop structure stably maintains single-strandedness of a target recognition sequence which interacts with a nucleic acid of interest for a gene of interest of a prokaryote, thereby providing a nucleic acid complex for effective silencing of the gene of interest.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: December 5, 2017
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Younghoon Lee, Geunu Bak, Hongmarn Park, Jee Soo Choi, Won Kyeong Kim, Shinae Suk, Ji Young Lee, Yeongseong Yoon
  • Patent number: 9827277
    Abstract: The invention concerns a composition made from at least one sulphated polysaccharide, in particular from an algae, and combined with at least one food ingredient. This composition can be used, in particular, in the field of food or in the treatment or prevention of an infection caused by microsporidia in humans or animals. It has useful properties as an antiparasitic agent in humans or animals; for the treatment or prevention of an infection caused by at least one microsporidia in humans or animals; in particular for the treatment or prevention of an infection caused in bees by the microsporidia Nosema, preferably Nosema ceranae or Nosema apis, or indeed for stimulating the immune defences of bees.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: November 28, 2017
    Assignees: UNIVERSITE BLAISE PASCAL—CLERMONT II, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Michaud, Celine Laroche, Aurore Villay, Michael Roussel, Marie Diogon, Hicham El Alaoui, Frederic Delbac
  • Patent number: 9822154
    Abstract: A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-KB-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.
    Type: Grant
    Filed: December 14, 2013
    Date of Patent: November 21, 2017
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, HEALTH RESEARCH, INC.
    Inventors: Xiang-Yang Wang, Xiaofei Yu, John R. Subjeck
  • Patent number: 9821047
    Abstract: The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 21, 2017
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum, Clara Jebet Sei
  • Patent number: 9821046
    Abstract: The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen, and wherein the particle comprises no, or substantially no, free hepatitis B surface antigen protein, and uses thereof.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: November 21, 2017
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Katharine Alice Collins, Sarah Catharine Gilbert, Adrian Vivian Sinton Hill
  • Patent number: 9804158
    Abstract: The present invention relates to peptides and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus Leishmania, especially infection with a South American strain causing the American Tegumentary Leishmaniasis (ATL).
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: October 31, 2017
    Assignees: Institut de Recherche pour le Développement, Universidad Peruana Cayetano Heredia
    Inventors: Jorge Arevalo, Eric Deharo, Angela Privat-Maldonado
  • Patent number: 9796762
    Abstract: The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: October 24, 2017
    Assignee: 4D Pharma Research Limited
    Inventors: Denise Kelly, Angela Patterson, Edouard Monnais, Imke Mulder
  • Patent number: 9789180
    Abstract: The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: October 17, 2017
    Assignee: The Regents of the University of California
    Inventors: Carolyn R. Bertozzi, Mary Sloan Siegrist Palmore, John C. Jewett, Chelsea G. Gordon, Peyton Shieh